Taiwan Biomaterial Co Ltd

Taiwan Biomaterial Co Ltd maintains a strong liquidity position, with a current ratio of 8.53 and cash and equivalents amounting to TWD 258.4 million. The company's debt-to-equity ratio is 0.08, indicating a conservative capital structure with minimal leverage. Free cash flow of TWD 76.98 million and operating cash flow of TWD 48.77 million further support its liquidity profile. The company's profitability is reflected in a return on equity (ROE) of 8.6% and a return on assets (ROA) of 7.46%. These metrics are in line with the industry's preferred focus on asset efficiency and capital returns. Gross profit of TWD 134.8 million and operating income of TWD 60.83 million suggest a healthy margin structure. The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic diversification data available in the current dataset. This lack of diversification may expose the company to regional or sector-specific risks. Outlook data indicates a stable growth trajectory, with no significant revenue changes expected in the current or next fiscal year. Historical revenue of TWD 220.4 million provides a baseline for future performance. Capital expenditure of TWD -3.14 million suggests minimal investment in new assets, which may limit future growth unless offset by organic expansion. Risk assessment shows low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce financial stressors. No dilution pressure is expected in the near term, as shares outstanding remain unchanged between basic and diluted counts. Recent filings and transcripts do not indicate any material events or strategic shifts. The company appears to be operating within a stable and predictable framework, with no disclosed regulatory or operational disruptions.